Mustang Bio (MBIO) Revenue & Revenue Breakdown
Mustang Bio Revenue Highlights
Mustang Bio Revenue by Period
Mustang Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Mustang Bio generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Mustang Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.88M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $-50.00K | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | -100.00% |
| 2018-03-31 | $50.00K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | - |
Mustang Bio generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Mustang Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ADAP | Adaptimmune Therapeutics | $60.28M | $128.37M |
| FBIO | Fortress Biotech | $59.66M | $13.03M |
| AFMD | Affimed | $8.28M | $155.00K |
| HSTO | Histogen | $3.77M | $5.00K |
| UNCY | Unicycive Therapeutics | $675.00K | - |
| ADTX | Aditxt | $645.18K | $44.28K |
| MGTA | Dianthus Therapeutics | $314.00K | $72.00K |
| CKPT | Checkpoint Therapeutics | $103.00K | $41.00K |
| NRBO | NeuroBo Pharmaceuticals | $7.00K | - |
| CRVS | Corvus Pharmaceuticals | - | - |
| APTO | Aptose Biosciences | - | - |
| MBIO | Mustang Bio | - | - |
| RVPH | Reviva Pharmaceuticals | - | - |
| LPTX | Leap Therapeutics | - | - |
| REVB | Revelation Biosciences | - | - |
| AKTX | Akari Therapeutics | - | - |
| DRMA | Dermata Therapeutics | - | - |
| ACHL | Achilles Therapeutics | - | - |
| AXLA | Axcella Health | - | - |
| KOD | Kodiak Sciences | - | - |
| SLRX | Salarius Pharmaceuticals | - | - |
MBIO Revenue FAQ
What is Mustang Bio’s yearly revenue?
Mustang Bio's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. MBIO's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Mustang Bio’s quarterly revenue?
Mustang Bio's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). MBIO's quarterly revenue for Q4 2023 was $2.88M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Mustang Bio’s revenue growth rate?
Mustang Bio's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.